Javier Martin-Broto, Sarcoma Medical Oncologist at the University Hospital Fundacion Jimenez Diaz, shared a post on LinkedIn:
“We’re thrilled to share the findings from the Clear Cell Sarcoma cohort in the IMMUNOSARC II trial. As far as we know, this represents only the third prospective study on CCS, and compares favorably with the two earlier trials involving MET inhibitors—in terms of response rates, progression-free survival, and overall survival.
This trial’s data show that the combination of sunitinib at 25 mg/day (following a 2-week induction at 37.5 mg/day) with nivolumab 240 mg every two weeks has meaningful clinical activity in advanced CCS. Highlights include a 6-month progression-free survival rate of 50.1%, an overall response rate of 14.3%, a CBR of 81%, and a notable group of long-term responders: five patients (21.7%) showed no disease progression at one year, with four of them remaining progression-free at 20 months among those who responded or stabilized. The median OS was 17 months. These outcomes offer a promising outlook for this treatment approach.”
Title: IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
Authors: Javier Martin-Broto, Sandra J. Strauss, Emanuela Palmerini, Claudia Valverde, Ana Sebio, Andres Redondo, Silvia Stacchiotti, Giovanni Grignani, Sandra Aliberti, Roberto Diaz-Beveridge, Enrique Gonzalez Billalabeitia, Josefina Cruz, Irene Carrasco-Garcia, Toni Ibrahim, Juan Diaz-Martin, Carmen Salguero-Aranda, Antonio Gutierrez, Empar Mayordomo-Aranda, Rafael Ramos, Jose Merino, Paola Collini, Roberto Tirabosco, Silvia Bague, Cleofe Romagosa, Maria Augusta Carrera, Patricio Ledesma, Nadia Hindi, David Silva Moura
Read the Full Article.
More posts featuring Javier Martin-Broto on OncoDaily.